Kim Seo Wan, Kim Namsoo, Choi Yu Jeong, Lee Seung-Tae, Choi Jong Rak, Shin Saeam
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
Dxome Co., Ltd., Seongnam-si 13558, Republic of Korea.
Cancers (Basel). 2024 Jul 5;16(13):2467. doi: 10.3390/cancers16132467.
Gene fusions are key drivers in acute leukemia, impacting diagnosis and treatment decisions. We analyzed 264 leukemia patients using targeted RNA sequencing with conventional karyotyping and reverse transcription polymerase chain reaction (RT-PCR). Leukemic fusions were detected in 127 patients (48.1%). The new guidelines introduced additional diagnostic criteria, expanding the spectrum of gene fusions. We discovered three novel fusions (, , and ). We analyzed recurrent breakpoints for the and rearrangements. Targeted RNA sequencing showed consistent results with RT-PCR in all tested samples. However, when compared to conventional karyotyping, we observed an 83.3% concordance rate, with 29 cases found only in targeted RNA sequencing, 7 cases with discordant results, and 5 cases found only in conventional karyotyping. For the five cases where known leukemic gene rearrangements were suspected only in conventional karyotyping, we conducted additional messenger RNA sequencing in four cases and proved no pathogenic gene rearrangements. Targeted RNA sequencing proved advantageous for the rapid and accurate interpretation of gene rearrangements. The concurrent use of multiple methods was essential for a comprehensive evaluation. Comprehensive molecular analysis enhances our understanding of leukemia's genetic basis, aiding diagnosis and classification. Advanced molecular techniques improve clinical decision-making, offering potential benefits.
基因融合是急性白血病的关键驱动因素,影响诊断和治疗决策。我们使用靶向RNA测序结合传统核型分析和逆转录聚合酶链反应(RT-PCR)对264例白血病患者进行了分析。在127例患者(48.1%)中检测到白血病融合。新指南引入了额外的诊断标准,扩大了基因融合的范围。我们发现了三种新的融合(、和)。我们分析了和重排的复发性断点。靶向RNA测序在所有测试样本中显示出与RT-PCR一致的结果。然而,与传统核型分析相比,我们观察到一致率为83.3%,29例仅在靶向RNA测序中发现,7例结果不一致,5例仅在传统核型分析中发现。对于仅在传统核型分析中怀疑存在已知白血病基因重排的5例病例,我们对其中4例进行了额外的信使RNA测序,结果证明不存在致病基因重排。靶向RNA测序被证明有利于快速准确地解释基因重排。同时使用多种方法对于全面评估至关重要。全面的分子分析增强了我们对白血病遗传基础的理解,有助于诊断和分类。先进的分子技术改善了临床决策,带来了潜在的益处。